For relapsed/refractory mantle cell lymphoma patients that previously treated with BTK inhibitors: The first part involves 6 cycles of combined therapy with zuberitamab, selinexor, dexamethasone, and thalidomide. This targeted combination regimen can enhance efficacy while reducing toxic side effects. The second part utilizes Zuberitamab plus selinexor for maintenance consolidation therapy, thereby reducing relapse and prolonging survival.
Ages 18-70, ECOG score 0-2(including ages 18 and 70);
Overall Survival > 6 months;
The diagnosis of mantle cell lymphoma was confirmed by histopathology. 4.At least one measurable lesion;
Refusing to take blood samples;
Previous allergies to any of the medications in the regimen;
Pregnant and lactating women;
The researchers believe that major diseases can cause interference in the trial.;
Zhengzhou University
Lead sponsor
The First Affiliated Hospital of Zhengzhou University
Sponsor institution